Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

NCITA Vision: Easy access to all forms of imaging

NCITA* have published a Comment article "Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers" in the British Journal of Cancer - https://www.nature.com/articles/s41416-021-01497-5.  This Comment article provides a comprehensive overview of the NCITA infrastructure and its goals to establish standardised protocols and locked-down quality-assured processes for clinical imaging biomarker qualification and a federated research data repository for secure data storage and sharing between multiple study sites.  The infrastructure support is available to clinical researchers in academia and industry through NCITA’s study adoption process.  International partners are also eligible to apply. While cancer imaging studies are a key focus, clinical research studies in other disease areas involving AI algorithm development, training and validation will also be considered for adoption. Through engagement with NHS Trusts, pharmaceutical companies, medical imaging and nuclear medicine companies as well as funding bodies and patient groups, NCITA aims to develop a robust imaging biomarker certification process, to revolutionise the speed and accuracy of cancer diagnosis, tumour classification and patient response to treatment.

*National Cancer Imaging Translational Accelerator (NCITA) is a national UK-wide medical imaging infrastructure which aims to accelerate the standardisation and translation of cancer imaging biomarkers for clinical use.  NCITA is led in Oxford by Professor Geoff Higgins who is part of the NCITA Governance Group, NCITA Engagement Group Chair and project lead for the [18F] FDOPA PET Imaging in Glioma (FIG Trial) and the ARCADIAN study, adopted by NCITA for image repository support.

Read more on NCITA's website

Similar stories

Communication at the crossroads of the immune system

In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team in Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.

Showcase success for Science Together research

A local collaboration teaming researchers from the University of Oxford and Oxford Brookes University with the Urban Music Foundation finished on a high note with an immersive sound and art installation at Oxford’s Old Fire Station.

Oxford spinout trials revolutionary bioelectronic implant to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their “smart” bioelectronic implants.

COVID-19 is a leading cause of death in children and young people in the US

A new study led by researchers at the University of Oxford’s Department of Computer Science has found that, between 2021 and 2022, COVID-19 was a leading cause of death in children and young people in the United States, ranking eighth overall. The results demonstrate that pharmaceutical and public health interventions should continue to be applied to limit the spread of the coronavirus and protect again severe disease in this age group.

Three or more concussions linked with worse brain function in later life

Experiencing three or more concussions is linked with worsened brain function in later life, according to new research.

New blood test could save lives of heart attack victims

Researchers in the Department of Physiology, Anatomy and Genetics (DPAG) have developed a blood test that measures stress hormone levels after heart attacks. The test – costing just £10 – could ensure patients receive timely life-saving treatment.